Coherus Oncology (CHRS) Q3 2026 earnings review
Coherus cuts staff to save cash, but drug sales slow
Coherus Oncology is shrinking its staff and drug pipeline to stretch its cash while sales of its main cancer drug slow down. Third-quarter sales of LOQTORZI rose 3% from the prior quarter to $14 million, missing the 10% to 15% quarterly pace management previously planned. Because of that slow climb, by our math the prior full-year outlook would require a 44% sales jump in the fourth quarter. To preserve cash, chief executive Denny Lanfear cut the workforce by 30% and dropped several clinical trial groups to focus on esophageal cancer.
| LOQTORZI cancer drug sales | $14.0M +3% from last quarter; +25% from a year ago |
|---|---|
| Loss per share, excluding one-offs | $0.20 $0.33 loss a year ago |
| Cash net of transition payables | $64M $83.6M total cash minus $19.6M owed, by our math |
| Sales needed to cover core burn | Cut $5M now $25–30M per quarter after 30% staff cut |
⚖️ Verdict: 🔴 Bearish
The story got worse because commercial growth stalled in the same quarter that the clinical pipeline narrowed and delayed key data. Dropping the head-and-neck cancer cohort and pushing the liver cancer readout into the first half of 2027 leaves investors waiting longer on a cash balance of $64 million after transition payables. The good news: shrinking the trial scope and staff lowers quarterly cash burn by $6 million to $7 million, cutting the quarterly sales needed for core breakeven to $25 million to $30 million.
The question now is whether existing cash and slower LOQTORZI growth can carry the biotech firm through its 2027 clinical readouts without selling more shares. Either the cost cuts and year-end liability wind-down stretch the runway far enough, or the company must tap its stock-sale program again. Fourth-quarter LOQTORZI sales and the year-end cash balance will tell.
🐂 Bull Case
Smaller Staff and Trial Scope Cut Cash Burn
Coherus Oncology, a cancer drug maker, has cut operating costs since exiting its copycat biologic drugs last year. In the third quarter, research and development fell 77 percentage points of revenue from a year ago, and sales and administrative spend dropped 67 points. Now the company is cutting its workforce by about 30% to match a narrower clinical pipeline.
Finance chief Bryan McMichael said the cuts are "lowering our core cash burn by $6 million to $7 million quarterly, which in turn lowers the quarterly LOQTORZI revenues required to cover core burn to $25 million to $30 million, down from $30 million to $35 million". Because sales are growing slowly, lowering the breakeven bar is the fastest way to shrink losses.
What to watch: combined research and administrative expenses over the next two quarters. A drop below $37 million per quarter would show the $6 million to $7 million in promised quarterly savings have arrived.
Esophageal Cancer Responses Give Tagmokitug a Focus
Tagmokitug is an experimental antibody designed to clear immune-suppressing cells from tumors so LOQTORZI, the company's approved immunotherapy drug, can attack the cancer. After reviewing data across several tumor types in October, chief executive Denny Lanfear made esophageal cancer the drug's lead target. Among 13 evaluable patients receiving the 700 mg dose in second-line esophageal cancer, tumors shrank in 33.3% of cases and 55.6% saw clinical benefit.
Patients lived a median of 5.5 months without their cancer worsening. Because second-line esophageal cancer has few effective options, Coherus plans to "pursue regulatory alignment on an expedited development path, initially focused on second-line esophageal cancer". Concentrating money on one responsive tumor type preserves cash while keeping a shot at a larger market.
What to watch: feedback from the Food and Drug Administration on the new second-line study design and the 700 mg dose. Agreement on a single registrational trial would confirm the expedited path.
Positives this quarter didn't test
Two commercial and funding drivers from prior quarters received no new numbers in the third-quarter release.
- Physician targeting tools: Coherus previously highlighted claims data covering 70% of patients and an artificial-intelligence education pilot, and a rebound in quarterly sales growth above 10% would show they are working.
- Outside-US licensing deals: management plans to license foreign rights to tagmokitug and casdozokitug as data mature, so any upfront cash payment would validate the October clinical data.
🐻 Bear Case
LOQTORZI Growth Slowed to 3% From Last Quarter
LOQTORZI is the only approved drug in the United States for recurrent or spreading nasopharyngeal carcinoma, a rare throat cancer. Chief executive Denny Lanfear said growing the drug's share against chemotherapy and unapproved immunotherapies can "provide a path to financial self-sufficiency". Last quarter, management forecast $57 million to $62 million in full-year sales and 10% to 15% average quarterly growth.
In the third quarter, LOQTORZI sales rose just 3% from the second quarter to $14.0 million, up 25% from a year ago. The press release did not repeat the full-year sales outlook and again gave no numbers for new patient starts or treatment duration. By our math, reaching the middle of the prior annual target would require $20.1 million in fourth-quarter sales, or a 44% jump in one quarter.
Even with the lowered breakeven target of $25 million to $30 million a quarter, LOQTORZI is only halfway there and barely gained ground this period. What to watch: fourth-quarter LOQTORZI net revenue. Another single-digit quarterly rise would leave full-year sales below the $57 million floor.
Coherus Dropped Head-and-Neck and Delayed Liver Data
Before this quarter, the clinical story rested on two near-term events: an October readout for tagmokitug in head-and-neck and colorectal cancers, and a fourth-quarter readout for casdozokitug, an antibody for first-line liver cancer. In this release, the biotech group chose to "deprioritize the other tagmokitug-toripalimab cohorts presented during our October 28, 2026, data release" and provided no response rates for them.
At the same time, Coherus said that "enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027". That pushes the liver cancer data back for a fourth time, from mid-2026 to late 2026 and now into next year. Shelving the head-and-neck cohort removes the largest near-term tumor target, while the liver delay consumes another quarter of cash before investors see results.
What to watch: the Phase 2 liver cancer readout in the first half of 2027. A clear tumor-response advantage over standard therapy is needed to keep a second pipeline program alive.
Cash Covers About Two Quarters Despite New Debt
Coherus has simplified its balance sheet since selling its copycat drugs, and supporters view the wind-down of transition liabilities as the final step to a clean operating model. However, total cash and marketable securities fell from $105.3 million in June to $83.6 million in September, even after the company refinanced its debt into a larger 2031 term loan.
- Cash net of transition payables: $64.0 million by our math, after subtracting $19.6 million owed for transition services
- Third-quarter operating cash burn: $34.0 million, down from $62.1 million in the second quarter
- Term loan debt: $52.6 million, up $15.3 million from June, triggering a $3.4 million debt-extinguishment loss
- Remaining accrued rebates and transition liabilities: $33.4 million combined, down only $4.2 million from June
Because clean cash of $64.0 million covers roughly two quarters of current cash burn, the company has little room before the 2027 liver cancer readout. What to watch: fourth-quarter operating cash burn and transition payables at year-end. If transition liabilities are not settled by December as planned, cash could fall below $35 million entering 2027.
💲 Other KPIs
Gross margin — the share of sales left after the cost of making the drug — rose 3.5 percentage points from a year ago and 1.0 point from the second quarter. Revenue from continuing operations grew 23.4% to $14.3 million while cost of goods sold rose only 10.0% to $4.1 million, lifting profit per dollar of LOQTORZI sold.
Weighted-average diluted shares rose 33.3% from 116.2 million a year ago after the cancer drug maker sold 32.9 million shares in a February public offering. The share count barely moved from 154.8 million in the second quarter, meaning the biotech firm did not tap its stock-sale program during the third quarter.
Inventory held steady against $14.1 million in June after rising more than fourfold from $3.2 million at the end of 2025. Chief executive Denny Lanfear noted that the manufacturing process transfer for toripalimab is now complete, ending the initial supply buildup that consumed working capital in the first half of the year.
🔮 Guidance
Lowered breakeven bar. Management cut the quarterly LOQTORZI sales needed to cover operating expenses excluding clinical trials by $5 million at the middle of the range, improving the profitability target. Finance chief Bryan McMichael said the 30% staff reduction and narrower trial scope will trim quarterly core cash burn by $6 million to $7 million over the next two quarters.
❓ Key Questions
Does the $57–62 million full-year LOQTORZI sales plan still stand?
The third-quarter release did not mention the full-year sales range issued in August. With nine-month LOQTORZI sales at $39.4 million, hitting the $57 million floor requires $17.6 million in the fourth quarter, or 26% growth from the third quarter.
What were the response rates in the dropped tagmokitug cohorts?
Coherus stopped advancing the non-esophageal cohorts from its October 28 data release, including head-and-neck and colorectal cancers, without printing their numbers in the earnings release. Knowing whether the drug failed on tumor shrinkage or durability helps judge its risk in esophageal cancer.
Why did the liver cancer readout slip to early 2027?
The Phase 2 trial of casdozokitug in first-line liver cancer finished enrolling patients in March 2026 and was slated for a fourth-quarter readout. Moving the first data release to the first half of 2027 stretches the wait while cash is tight.
What will the 30% staff cut cost in cash severance?
Reducing headcount by 30% will save $6 million to $7 million a quarter over the next two quarters, but the release did not state the one-time severance charge. Those upfront payments will draw from the $64.0 million in clean cash.